SNY's Subcutaneous Sarclisa Proves Non-Inferior to IV Formulation (Revised)

Published on 14 Jan 2025 on Zacks · via Yahoo Finance

Sanofi's Sarclisa SC formulation shows non-inferiority versus Sarclisa IV infusion in a late-stage...

Read the rest of the article

Start tracking your investments with Statfolio

We recently compiled a list of the 15 Best Cheap Stocks to Buy for 2025. In this article, we are...

Insider Monkey · via Yahoo Finance 19 Jan 2025

We recently compiled a list of the Louis Navellier’s Top 15 Long-Term Stock Picks. In this articl...

Insider Monkey · via Yahoo Finance 18 Jan 2025

On Friday, the U.S. Department of Health and Human Services (HHS) unveiled the selection of 15...

Benzinga · via Yahoo Finance 17 Jan 2025

We recently published a list of 15 Best NASDAQ Dividend Stocks To Buy. In this article, we are go...

Insider Monkey · via Yahoo Finance 16 Jan 2025

Sanofi's Sarclisa SC formulation shows non-inferiority versus Sarclisa IV infusion in a late-stag...

Zacks · via Yahoo Finance 14 Jan 2025

U.S. stocks mixed at close of trade; Dow Jones Industrial Average up 0.85%

Investing.com 13 Jan 2025

(NASDAQ: REGN), reducing the price target to $950 from $1,000, while still recommending the stock...

Investing.com 10 Jan 2025

But just like anyone else, they could be wrong. If multiple institutions change their view on a...

Simply Wall St. · via Yahoo Finance 24 Dec 2024

The strategy involves buying the 10 highest-yielding stocks in the Dow Jones Industrial Average.,...

Barrons.com 24 Dec 2024

(Bloomberg) -- Disappointing trial results for Novo Nordisk A/S’s experimental obesity shot cappe...

Bloomberg · via Yahoo Finance 23 Dec 2024